Please use this identifier to cite or link to this item: http://hdl.handle.net/10637/12653

Association of hypertension with all-cause mortality among hospitalized patients with COVID-19


Thumbnail

See/Open:
 Association_Rodilla_JOCM_2020.pdf
1,45 MB
Adobe PDF
Title: Association of hypertension with all-cause mortality among hospitalized patients with COVID-19
Authors : Rodilla Sala, Enrique
Saura Vinuesa, Alberto
Jiménez Pérez de Heredia, Iratxe
Mendizábal Núñez, Andrea
Pineda Cantero, Araceli
Lorenzo Hernández, Elizabeth
Keywords: COVID-19 - Pacientes - Mortalidad.COVID-19 (Disease) - Patients - Mortality.Hipertensión.SARS-CoV-2 (Virus) - Pacientes - Mortalidad.Hypertension.SARS-CoV-2 (Virus) - Patients - Mortality.
Publisher: MDPI
Citation: Rodilla, E., Saura, A., Jiménez, I., Mendizábal, A., Pineda-Cantero, A., Lorenzo-Hernández, E. et al. (2020). Association of hypertension with all-cause mortality among hospitalized patients with COVID-19. Journal of Clinical Medicine, vol. 9, i. 10 (28 sep.), art. 3136. DOI: https://doi.org/10.3390/jcm9103136
Abstract: It is unclear to which extent the higher mortality associated with hypertension in the coronavirus disease (COVID-19) is due to its increased prevalence among older patients or to specific mechanisms. Cross-sectional, observational, retrospective multicenter study, analyzing 12226 patients who required hospital admission in 150 Spanish centers included in the nationwide SEMI-COVID-19 Network. We compared the clinical characteristics of survivors versus non-survivors. The mean age of the study population was 67.5 16.1 years, 42.6% were women. Overall, 2630 (21.5%) subjects died. The most common comorbidity was hypertension (50.9%) followed by diabetes (19.1%), and atrial fibrillation (11.2%). Multivariate analysis showed that after adjusting for gender (males, OR: 1.5, p=0.0001), age tertiles (second and third tertiles, OR: 2.0 and 4.7, p=0.0001), and Charlson Comorbidity Index scores (second and third tertiles, OR: 4.7 and 8.1, p = 0.0001), hypertension was significantly predictive of all-cause mortality when this comorbidity was treated with angiotensin-converting enzyme inhibitors (ACEIs) (OR: 1.6, p = 0.002) or other than renin-angiotensin-aldosterone blockers (OR: 1.3, p = 0.001) or angiotensin II receptor blockers (ARBs) (OR: 1.2, p = 0.035). The preexisting condition of hypertension had an independent prognostic value for all-cause mortality in patients with COVID-19 who required hospitalization. ARBs showed a lower risk of lethality in hypertensive patients than other antihypertensive drugs.
Description: Este artículo se encuentra disponible en la siguiente URL: https://www.mdpi.com/2077-0383/9/10/3136
En este artículo también participan: Maria del Pilar Fidalgo-Montero, Joaquín Fernandez López-Cuervo, Ricardo Gil-Sánchez, Elisa Rabadán-Pejenaute, Lucy Abella-Vázquez, Vicente Giner-Galvañ, Marta Nataya Solís-Marquínez, Ramon Boixeda, Andrés de la Peña-Fernández, Francisco Javier Carrasco-Sánchez, Julio González-Moraleja, José David Torres-Peña, María Esther Guisado-Espartero, Joaquín Escobar-Sevilla, Marcos Guzmán-García, María Dolores Martín-Escalante, Ángel Luis Martínez-González, José Manuel Casas-Rojo y Ricardo Gómez-Huelgas.
Este artículo pertenece al número especial "Coronavirus disease 2019 (COVID-19) pandemic: current knowledge and future perspectives".
URI: http://hdl.handle.net/10637/12653
Rights : http://creativecommons.org/licenses/by/4.0/deed.es
ISSN: 2077-0383 (Electrónico).
Issue Date: 28-Sep-2020
Center : Universidad Cardenal Herrera-CEU
Appears in Collections:Dpto. Medicina y Cirugía





Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.